Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma ; volume:8 ; number:1 ; day:27 ; month:8 ; year:2018 ; pages:1-13 ; date:12.2018
Scientific reports ; 8, Heft 1 (27.8.2018), 1-13, 12.2018

Urheber
Wu, Wei-De
Beteiligte Personen und Organisationen
Chen, Pin-Shern
Omar, Hany A.
Arafa, El-Shaimaa A.
Pan, Hung-Wei
Jeng, Jingyueh
Hung, Jui-Hsiang
SpringerLink (Online service)

DOI
10.1038/s41598-018-31209-8
URN
urn:nbn:de:101:1-2018092810264959152747
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:26 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.

Objekt beim Datenpartner anzeigen

Beteiligte

  • Wu, Wei-De
  • Chen, Pin-Shern
  • Omar, Hany A.
  • Arafa, El-Shaimaa A.
  • Pan, Hung-Wei
  • Jeng, Jingyueh
  • Hung, Jui-Hsiang
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Cholesterol-conjugated let-7amimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy

Cholesterol-conjugated let-7amimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma

Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy

Verbundene Objekte